• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

NIHR Oxford Health Biomedical Research Centre

Improving brain health: the future in mind

MENUMENU
  • Our People
  • About
    • About
    • Contact
    • Core facilities
    • Management and partners
    • Work with us
  • Clinical Research Facility
    • Who we are
    • What we do
    • Our staff
    • Our facilities
    • Our collaborators
    • List of open research studies
    • Get involved
    • CRF publications
    • Where to find us
  • Research Themes
    • Overview of Research Themes
    • Adult Mental Health
    • Older Adults and Dementia
    • Precision Psychological Therapies
    • Clinical Research Infrastructure and Experimental Medicine
    • Informatics and Digital Health
    • Neuroimaging and Cognitive Neuroscience
    • Patient and Public Involvement
    • Training theme
    • Theme Leads
  • Our Work
    • Brain Health Centre
    • Oxford Precision Psychiatry Lab (OxPPL)
    • Oxford Dementia and Ageing Research (OxDARE)
    • Treatment Resistant Depression Clinic
    • Experimental Medicine and Industry Partnership (EMIP)
  • COVID-19 Research
    • Overview
    • News
    • COVID-19 & clinical management of mental health issues
  • News & Events
    • News
    • Blog
    • Training & Events
    • Psychiatry department seminars
  • Training Hub
  • Patients & Public
    • About Patient and Public Involvement
    • Shape our research
    • Take part in our research
    • Resources for researchers
    • Resources for the public
    • Patient and Public Involvement Strategy
    • Young people’s involvement
You are here: Home / NIHR Oxford cognitive health Clinical Research Facility / List of open research studies

NIHR OXFORD COGNITIVE HEALTH
CLINICAL RESEARCH FACILITY

List of open research studies


Please find below a list of currently open research studies at our CRF.

During 2020/21 our activity adapted to the COVID-19 crisis in line with the priorities set by the NIHR and Public Health England.

► COVID-19

C-MORE

Capturing multi-organ effects of COVID-19.

COVID-CNS

The COVID-19 Clinical Neuroscience Study.

► Dementia and cognitive impairment

DFP

Deep and Frequent Phenotyping: Combinatorial Biomarkers for Dementia Experimental Medicine.

DPUK Tau (PREVENT Sub study)

Assessing Models of AD risk and progression in existing cohorts using Tau PET imaging in combination with prospective follow-up.

ENCRYPT (PREVENT Sub study)

The Entorhinal CoRtex-hippocampal circuit in PREVENT (ENCRYPT) study.

MND

A study to characterise C9orf72 patients and asymptomatic carriers.

NTAD

New Therapeutics in Alzheimer’s Disease – MEG biomarker platform development.

PREVENT

Previous research suggests there can be a variety of markers of dementia before the presentation of symptoms. The Prevent study aims to investigate participants between the ages of 40 and 59 years old in their exposure to risk factors before dementia onset. It is a longitudinal and cross-sectional study which means that the study is ongoing and will take a snapshot of participants at consecutive 2 – 6-year time gaps throughout their middle age. At each of these visits, a series of assessments are carried out to investigate a wide range of risk factors, including cognitive performance, biomarkers, and brain structural/functional changes. The study is thorough, aiming to identify any other risk factors with possible links to dementia onset, including a family history of dementia, life stressors, drug use, alcohol intake, sleep quality, exposure to contact sports and physical activity. The study has been running at the Clinical Research Facility (CRF) since 2017, and participants will be coming up to their 3rd visit as we approach 2023. The CRF is incredibly grateful to all Prevent participants who have already volunteered their time and contributed so much to the trial.

RADAR-AD

Remote assessment of Disease and Relapse – Alzheimer’s Disease.

► Healthy volunteers

ZOGENIX

The effect of seven day fenfluramine administration on cognition in healthy volunteers.

► Mood

APFEMA

Analysing Patients’ Facial Expressions to improve Mood Assessment.

ATP

A randomised, placebo-controlled, double-blind trial of the antidepressant efficacy of a novel CNS-penetrant PX27 receptor antagonist, JNJ-54175446, in people with major depressive disorder, an incomplete response to monoaminergic antidepressant drugs, and a biomarker profile of active PX27 signalling.

Janssen Adolescent

This study aims to find out whether seltorexant (JNJ-42847972) could be used as an add-on treatment, along with your current anti-depressant medication, to treat depression (Major Depressive Disorder) that has not responded to current antidepressant medication (SSRI) and psychotherapy.

LQD

Lithium and quetiapine for treatment resistant depression.

PAX-D

Randomised, placebo-controlled trial evaluating the efficacy and mechanism of Pramipexole as add-on treatment for people with treatment resistant depression.

RELAKS

Reward, Emotion, Learning, and Ketamine study.

RESTAND

The effects of PF-04995274 on emotional processing in unmedicated depressed patients.

RESTART

The effects of PF-04995274 on emotional processing in treatment-resistant, medicated, depressed patients.

SUSTAIN-3

An open-label long-term extension safety study of intranasal esketamine in treatment-resistant depression safety and sustenance of esketamine treatment response with repeated doses at intervals determined by symptom severity (SUSTAIN-3).

► Other

ALKERMES

A study to evaluate the effect of ALKS 3831 compared to olanzapine on body weight in young adults with schizophrenia, schizophreniform, or bipolar I disorder who are early in their illness.

PATTERN

The Physical and menTal healTH – ExploRatioN study.

► Psychosis

BI CACT

A phase II randomized, double-blinded, placebo-controlled parallel group trial to examine the efficacy and safety of BI 425809 once daily with adjunctive Computerized Cognitive Training over 12 week tratment period in patients with Schizophrenia.

Biogen

A phase 2, randomised, double-blind, multiple-dose, placebo-controlled study to evaluate the safety and efficacy of BIIB104 in Subjects with Cognitive Impairment Associated with Schizophrenia (CIAS).

SINAPPS2

A randomised phase II double-blinded placebo-controlled trial of intravenous immunoglobulins and rituximab in patients with antibody-associated psychosis.

We are trained to deliver validated scales to measure your mood and your cognitive functioning (the ability to think, learn, and remember).

Primary Sidebar

NIHR Oxford cognitive health Clinical Research Facility

  • New funding for Oxford Health Clinical Research Facility
  • Who we are
  • What we do
  • Interactive seminar on research methods
  • Our staff
  • Our facilities
  • Our collaborators
  • List of open research studies
  • Get involved
  • CRF publications
  • Where to find us

Tweets by @OxHealthBRC

Tweets by OxHealthBRC
Follow @OxHealthBRC

Footer

Follow us

  • Twitter
  • YouTube

Improving brain health: the future in mind

The National Institute for Health Research (NIHR) Biomedical Research Centre (BRC) is a partnership between Oxford Health NHS Foundation Trust and the University of Oxford. We are part of the Oxford Academic Health Science Centre.

Oxford Academic Health Science Centre
  • Sitemap
  • Accessibility
  • Disclaimer
  • Cookies
  • Contact

© 2022 NIHR Oxford Health Biomedical Research Centre · Log in

Cookies

This site uses cookies: See our privacy policy